Alzheimer’s disease is a disease which cannot be cured completely. In this aspect ribonucleic acid interference (RNAi) therapy is a prospective therapeutic mechanism which can be used for identifying a future curative procedure. RNAi therapy comprises small interfering RNA (siRNA), short hairpin (shRNA) and micro-RNA therapeutics. Within these three mechanisms we have identified two of them as an effective method of combating this genetic incurable disease. siRNAs and shRNAs are very much effective in vitro that is already proved in many research work. In our study we have used a very potent, biocompatible nanoparticle-layered double hydroxide for delivering these macromolecules. However, the intercalation and cellular internalization of these macromolecules demonstrated significant differences. As siRNAs have low-molecular weight than shRNAs they demonstrated different characteristics in the case of internalization within layered-double hydroxide and while cellular internalization. At the end of this study it has been found that both of these macromolecules may be used as a therapeutic approach of Alzheimer’s disease after studying it in future in animal and human subjects.

中文翻译：

---

层状双氢氧化物纳米偶联物在小干扰和短发夹核糖核酸递送中的体外比较研究

阿尔茨海默病是一种无法完全治愈的疾病。在这方面，核糖核酸干扰 (RNAi) 疗法是一种前瞻性的治疗机制，可用于确定未来的治愈程序。RNAi 疗法包括小干扰 RNA (siRNA)、短发夹 (shRNA) 和微 RNA 疗法。在这三种机制中，我们已经确定其中两种是对抗这种遗传不治之症的有效方法。siRNA 和 shRNA 在体外非常有效，这已在许多研究工作中得到证实。在我们的研究中，我们使用了一种非常有效的、生物相容的纳米颗粒层状双氢氧化物来传递这些大分子。然而，这些大分子的嵌入和细胞内化表现出显着差异。由于 siRNA 具有比 shRNA 低的分子量，因此它们在层状双氢氧化物内化和细胞内化的情况下表现出不同的特征。在这项研究的最后发现，在未来对动物和人类受试者进行研究后，这两种大分子都可以用作阿尔茨海默病的治疗方法。